Analyst Price Targets — KPTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 9, 2026 8:20 pm | — | UBS | $28.00 | $8.49 | TheFly | Karyopharm initiated with a Buy at Rodman & Renshaw |
| December 17, 2025 12:01 pm | — | Goldman Sachs | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| December 17, 2025 12:01 pm | — | Piper Sandler | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| November 4, 2025 2:49 pm | Brian Abrahams | RBC Capital | $19.00 | $5.60 | TheFly | Karyopharm price target lowered to $19 from $30 at RBC Capital |
| October 13, 2025 10:10 am | Robert Burns | H.C. Wainwright | $15.00 | $5.50 | TheFly | Karyopharm upgraded to Buy from Neutral at H.C. Wainwright |
| October 9, 2025 11:13 am | — | Robert W. Baird | $21.00 | $5.90 | TheFly | Karyopharm price target lowered to $21 from $25 at Baird |
| October 8, 2025 6:56 pm | — | Leerink Partners | $6.00 | $5.91 | TheFly | Karyopharm price target lowered to $6 from $8 at Leerink |
| June 10, 2024 5:39 am | Brian Abrahams | RBC Capital | $3.00 | $0.95 | StreetInsider | RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI) |
| January 10, 2023 4:30 am | — | Leerink Partners | $5.00 | $2.84 | Benzinga | SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $5 |
| August 23, 2022 11:57 am | Collen Kusy | Robert W. Baird | $14.00 | $5.56 | Pulse 2.0 | Karyopharm (KPTI) Stock: $14 Target And Outperform Rating |
Latest News for KPTI
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report)'s stock price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $7.99 and traded as high as $9.00. Karyopharm Therapeutics shares last traded at $8.94, with a volume of 185,839 shares trading hands. Analyst Ratings
Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totaling 3,592,118 shares, an increase of 20.9% from the February 26th total of 2,971,195 shares. Approximately 19.9% of the company's shares are short sold.
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KPTI.
U.S. House Trading
No House trades found for KPTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.